Vladislav E. Bugaev

Vladislav E. Bugaev

Auto-generated profile, based on publicly available information

Vladislav E. Bugaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
ХСХэнянь Сунь
Хэнянь Сунь
СНСергей Неред
Сергей Неред
АТАлексей Трякин
Алексей Трякин
ВБВладислав Бугаев
Владислав Бугаев
АСАнна Строганова
Анна Строганова
ИСИван Стилиди
Иван Стилиди
Актуальность. Периоперационная химиотерапия является стандартом лечения пациентов с местно-распространенным резектабельным раком желудка (РЖ). Частота и эффективность периоперационной химиотерапии (ХТ) в зависимости от наличия микросателлитной нестабильности (MSI) у пациентов, получивших преоперационную терапию, остается неясной. Цель. Изучить эффективность периоперационной терапии у больных РЖ с разным уровнем MSI. Материалы и методы. В исследование включены 173 больных местно-распространенным РЖ, получивших периоперационную терапию в ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России. У всех больных проводился тест на микросателлитную нестабильность (MSI-H) с помощью BAT25, BAT26, NR21, NR24, NR27. Оценивалась степень патоморфологического регресса (TRG) по A.M. Mandard, безрецидивная (БРВ) и общая (ОВ) выживаемость. Результаты. В 17 (9,82 %) случаях выявлена MSI-H. Высокая степень TRG выявлена у 15,17 % больных с MSS статусом, 0 из 12 больных — с MSI, получавших FLOT или FOLFIRINOX, и у 3 из 5 больных, получавших химиоиммунотерапию. 6-месячная БРВ у больных с MSS составила 93 % против 58 % у больных MSI-H, получивших ХТ, и 100 % — у больных из группы химиоиммунотерапии (р = 0,034). Выводы. Наши данные показывают, что результаты системной периоперационной ХТ с использованием современных режимов у больных с MSI-H-статусом хуже, чем у больных с MSS-статусом. Добавление ниволумаба к химиотерапии позволили достичь высокой частоты (60 %) полного патоморфологического регресса у группы пациентов с MSI-H статусом.

23 June 2023 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
HSH. Sun
H. Sun
SNS. N. Nered
S. N. Nered
ATAlexey Tryakin
Alexey Tryakin
EAE. V. Artamonova
E. V. Artamonova
AKA. E. Kalinin
A. E. Kalinin
ISI. S. Stilidi
I. S. Stilidi
Background. microsatellite instability (MSI) is a prognostic marker of survival in many malignant diseases and show resistance to chemotherapy at early stages of colorectal cancer and show no benefits from chemotherapy at early stages of colorectal cancer. However, the role of MSI in resectable gastric cancer (GC) remains unknown.Aim. To study the results of treatment of resectable gastric cancer with microsatellite instability.Materials and methods. The study included 286 patients with resectable gC who received treatment at the N. N. Blokhin national medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the mandard tumour regression score, including disease-free survival and overall survival.Results. MSI indicated in 27 cases (9.44 %) out of 286 resectable gastric cancer. In group patients who received only surgical treatment, 2-year disease-free survival in patients with MSI-H was 77.80 % versus 88.29 % in MSS patients (hazard ratio (HR) 1.82, 95 % confidence interval (CI) 0.37–8.82, p = 0.45), 2-year overall survival in patients with MSI-H was 88.90 % versus 95.36 % in MSS patients (HR 2.03, 95 % CI 0.20–19.8, p = 0.54). In patients who received perioperative chemotherapy, 28.57 % (4 / 14) had progression in MSI-H tumor versus 3.61 % (6 / 166) in MSS tumor (p 0.001). In group patients who received treatment combined with chemotherapy, 2-year disease-free survival in patients with MSI-H was 59.60 % versus 67.36 % (HR 1.96, CI 95 % 0.88–4.35, p = 0.09), 2-year overall survival in patients with MSI-H was 67.30 % versus 85.86 % in MSS patients (HR 1.86, 95 % CI 0.64–5.41, p = 0.25)Conclusion. MSI-H is not a favorable prognosis factor in patients with resectable GC who are treated surgically combined with chemotherapy. The prevalence of progression in patients with MSI-H-status is higher than MSS-status with perioperative chemotherapy (FLOT / FOLFIRINOX).

31 December 2019 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
VBVladislav E. Bugaev
Vladislav E. Bugaev
MNMaxim Petrovich Nikulin
Maxim Petrovich Nikulin
SNSergey N. Nered
Sergey N. Nered
LLLudmila N. Lyubchenko
Ludmila N. Lyubchenko
ISIvan S. Stilidi
Ivan S. Stilidi
ЛНЛюбченко Людмила Николаевна
Любченко Людмила Николаевна
Relevance. Leiomyosarcomas is highly aggressive tumors with poor prognosis. Surgical resection is a standard treatment approach. However, data of long-term results of surgical treatment are lacking due to rarity of retroperitoneal form of leiomyosarcoma. Prognostic significance of tumor size, grade and recurrence type remains unclear as well. Aim. To analyze results of surgical treatment of patients with retroperitoneal leiomyosarcoma and to define prognostic factors which are associated with disease-free and overall survival. Materials and methods. The study included patients with primary retroperitoneal leiomyosarcomas who have received surgical or combined treatment between January 2003 and April 2019 at Blokhin National Medical Research Centre of Oncology. Short- and long-term clinical outcomes of surgical and combined treatment as well as recurrence rate, pattern of recurrence and morphological features were analyzed in order to define prognostic factors of disease-free and overall survival. Results. The study included 64 patients with primary retroperitoneal leiomyosarcomas 12 men (18%) and 52 women (82%). Median tumor size was 10.55.0 cm. Most of the operations (93.3%) were done by open approach. Combined resections were performed in 62.5% of cases (n=40), vascular resections in 17.2% cases (n=11). Radical (R0) resections were performed in 54 cases (85.9%). Postoperative morbidity and mortality rate were 39% and 0% respectively. Adjuvant chemotherapy or radiotherapy received 21 (35%) patients and 1 (1.7%) patient respectively. 46 (71.9%) patients had a disease recurrence. Recurrence type (local recurrence/distant metastases) did not influence overall survival (р=0.655). Median disease-free survival was 27 months (95% CI 1043.9). 3-year and 5-year disease-free survival was 43% and 21% respectively. Median overall survival was 79 months (95% CI 49108.9). 3-year and 5-year overall survival was 73% and 59% respectively. Among patients grade 2 and grade 3 tumors median disease-free survival was 49 vs. 18 months (р=0.271), median overall survival 146 vs. 58 months (р=0.018). There were no statistically significant differences in rate of radical resections among patients with different tumor location (р=0.804) or its size (р=0,520). Patients, who have undergone radical (R0) resection, had better overall (р=0.028) and disease-free survival (р0.001). Adjuvant chemotherapy was not associated lower risk of disease recurrence (p=0.976), type of recurrence (р=0.981) and lower overall survival (р=0.284). Conclusion. Tumor grade and radical resection are the most important prognostic factors in patients with retroperitoneal leiomyosarcoma. In our study, tumor size was not correlated with long-term results and possibility of radical resection.

24 December 2016 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
VBVagan U. Bokhian
Vagan U. Bokhian
APAlentina I. Pavlovskaya
Alentina I. Pavlovskaya
AKAlina A. Kolomeytseva
Alina A. Kolomeytseva
VBVladislav E. Bugaev
Vladislav E. Bugaev
ISIvan S. Stilidi
Ivan S. Stilidi
Адренокортикальный рак (АКР) имеет высокий злокачественный потенциал в преобладающем большинстве случаев, однако у некоторых больных АКР характеризуется вялым, неагрессивным течением, когда пациенты с доказанными отдаленными метастазами или рецидивом могут жить без прогрессирования достаточно продолжительное время. Индолентный курс АКР определен как отсутствие роста доказанных злокачественных опухолевых узлов за период 12 мес. и более. Проведен сравнительный анализ клинико-морфологических характеристик 7 больных с индолентным АКР в сравнении с контрольной группой, состоящей из 157 больных, оперированных по поводу АКР. Изучены клинические характеристики, гистологические критерии Вейса, индекс пролиферативной активности Ki67, экспрессия белка р53, b-катенина. У 7 пациентов, оперированных многократно (до 5 раз), отмечено индолентное течение рецидивного или метастатического АКР. Максимальный срок наблюдения, когда отсутствовал рост опухоли, составил более 37 мес. Клинические характеристики больных обеих групп достоверно не отличались. Гистологические критерии Вейса, индекс Ki67, экспрессия белка р53 также достоверно не отличались. Экспрессия b-катенина, как ядерная, так и цитоплазматическая, отсутствовала в клетках АКР с индолентным течением, различия по сравнению с контрольной группой достоверны. Индолентное течение обусловлено биологическими особенностями опухоли, не отражается в клинических показателях, характеризующих первичную опухоль. Возможно, одним из механизмов, приводящих к подобному течению заболевания, является инактивация сигнального пути Wnt/b-катенин. Феномен индолентного течения АКР, характеризующегося, как правило, высоким злокачественным потенциалом, требует дальнейших исследований.

25 December 2024 in Russian Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZBZurab A. Bagateliya
Zurab A. Bagateliya
DGDmitrii N. Grekov
Dmitrii N. Grekov
SLSergey S. Lebedev
Sergey S. Lebedev
ACAntonio K. Chekini
Antonio K. Chekini
VYVictor N. Yakomaskin
Victor N. Yakomaskin
ЯНЯкомаскин Виктор Николаевич
Якомаскин Виктор Николаевич
BACKGROUND: The sensitivity of computer tomography (CT) guided transthoracic needle biopsy for the verification of lung tumors is reported to range from 74 to 90%. An augmented reality robotic navigation system for CT-guided percutaneous lung biopsy has been developed to facilitate more precise biopsy of lung lesions. The present study describes the authors’ experience with the navigation system for transthoracic lung biopsy. AIM: To analyze the safety and diagnostic value of performing a transthoracic biopsy of lung tumors using a robotic CT navigation system. MATERIALS AND METHODS: The study included a retrospective analysis of CT-guided robot-assisted transthoracic lung biopsy procedures performed in the Thoracic and Abdominal Surgical Oncology Department No. 72 of the Botkin Moscow General Scientific and Clinical Center between November 30, 2023 to April 04, 2024. A total of 104 patients were included in the study. The biopsy was performed following the developed algorithm. RESULTS: The specimens obtained were morphologically valuable in 91.8% of cases (n=101/110). A total of 1–4 specimens (tissue columns) were obtained from each patient during the biopsy procedure. Specifically, 1 specimen was obtained from 7 patients (6.4٪), 2 specimens from 57 patients (51.8٪), 3 specimens from 43 patients, and 4 specimens from 3 patients (2.7٪). Among the patients for whom morphologically valuable specimens were obtained (n=101), the diagnosis of malignant tumor was confirmed in 76 cases (75.2%). In all remaining cases (n=25, 24.8%), benign lesions or inflammatory/post-inflammatory changes were diagnosed. Complications of various severity degrees occurred in 17 cases (15.5%). No deaths were reported (0%). The findings revealed no statistically significant differences in the frequency of cases with a verified diagnosis based on the diameter of the biopsy needle (p=0.124). Furthermore, the analysis revealed no statistically significant effect of the diameter of the biopsy needle (16G or 18G) on the overall complication rate (18.2 and 9%, respectively; p=0.266) and the frequency of pleural drainage for postoperative pneumothorax (10.4 and 6%, respectively; p=0.72). CONCLUSIONS: The CT-guided robot-assisted transthoracic lung biopsy is a safe and effective technique for the morphological verification of malignant tumors.

21 December 2025 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
IBI. M. Borovkov
I. M. Borovkov
DSD. D. Sekhniaidze
D. D. Sekhniaidze
IEI. V. Eltsov
I. V. Eltsov
VBV. E. Bugaev
V. E. Bugaev
PKP. V. Kononets
P. V. Kononets
Background. Thoracoscopic approach was proved to be safe and effective for surgical treatment of patients with locally advanced lung cancer. However, the role of this approach in pneumonectomy has not been sufficiently studied which limits its use. Aim. To develop and implement an original safe surgical technique of thoracoscopic multiport pneumonectomy and to compare immediate surgical outcomes of open surgery and thoracoscopic (both uniport and multiport) approaches. Materials and methods. Retrospective analysis included data on patients who underwent open and thoracoscopic pneumectomy due to lung cancer between 2016 and 2023. Inclusion criteria were primary resectable lung cancer, age between 18 and 75 years, ECOG performance status 0–2. Study design involved an exploratory pilot study aimed at evaluation of immediate results of thoracoscopic pneumectomy and the rate of postoperative complications. Results. A total of 100 patients were included in study, of which 51 underwent open pneumonectomy and 49 – minimally invasive pneumonectomy, including both uniport (n = 20) and multiport (n = 29) approaches. Between the groups of thoracoscopic and open pneumectomy no differences were found in the number of dissected lymph nodes (19.1 and 22.3, respectively; p = 0.06) and the rate of R0-resections (100 and 94.1 %; p = 0.226). Median operative time was 200 min with mean values of 211.9 min in the thoracoscopy group and 210.9 min in the open surgery group (p = 0.617). Operative time did not correlate with the side of surgical intervention (p = 0.312) or the type of surgical approach (p = 0.939). Thoracoscopic pneumonectomy was associated with lower average length of hospital stay (p = 0.086) and lower duration of postoperative opioid consumption (p = 0.001) compared to open surgery. Conclusion. The obtained data show that thoracoscopic approach for pneumonectomy is equally effective as thoracotomy and decreases duration of postoperative in-hospital treatment and use of opioid analgesics. However, considering retrospective character of the study, further data validation in a prospective study is planned.